Bristol Myers Squibb

Bain, CPP and Bristol Myers Add $126M to Beeline's Lupus Pipeline

Beeline Medicines closed a $126.3 million Series A extension from Bain Capital, CPP Investments and Bristol Myers Squibb, upsizing its total Series A to $426.3 million to fund pivotal development of afimetoran in lupus ahead of a Phase 2 readout expected in.